142 related articles for article (PubMed ID: 20630668)
1. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.
Alonzi R; Padhani AR; Taylor NJ; Collins DJ; D'Arcy JA; Stirling JJ; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):721-7. PubMed ID: 20630668
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
3. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.
Barrett T; Gill AB; Kataoka MY; Priest AN; Joubert I; McLean MA; Graves MJ; Stearn S; Lomas DJ; Griffiths JR; Neal D; Gnanapragasam VJ; Sala E
Magn Reson Med; 2012 Mar; 67(3):778-85. PubMed ID: 22135228
[TBL] [Abstract][Full Text] [Related]
4. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
[TBL] [Abstract][Full Text] [Related]
5. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Dean JP; Sprenger CC; Wan J; Haugk K; Ellis WJ; Lin DW; Corman JM; Dalkin BL; Mostaghel E; Nelson PS; Cohen P; Montgomery B; Plymate SR
J Clin Endocrinol Metab; 2013 May; 98(5):E820-8. PubMed ID: 23533230
[TBL] [Abstract][Full Text] [Related]
6. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging.
Padhani AR; MacVicar AD; Gapinski CJ; Dearnaley DP; Parker GJ; Suckling J; Leach MO; Husband JE
Radiology; 2001 Feb; 218(2):365-74. PubMed ID: 11161148
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727).
Dal Pra A; Milosevic M; Hill R; Wouters B; Warde P; Bristow RG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1319. PubMed ID: 22385713
[No Abstract] [Full Text] [Related]
8. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
[TBL] [Abstract][Full Text] [Related]
9. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
Prapotnich D; Cathelineau X; Rozet F; Barret E; Mombet A; Cathala N; Sanchez-Salas RE; Vallancien G
World J Urol; 2009 Oct; 27(5):627-35. PubMed ID: 19247669
[TBL] [Abstract][Full Text] [Related]
10. Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?
Christie DR; Sharpley CF; Mitina N; MacAteer E; Jackson JE; Lunn D
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):287-292. PubMed ID: 32174016
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
12. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
13. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate.
Alonzi R; Taylor NJ; Stirling JJ; d'Arcy JA; Collins DJ; Saunders MI; Hoskin PJ; Padhani AR
J Magn Reson Imaging; 2010 Jul; 32(1):155-64. PubMed ID: 20578023
[TBL] [Abstract][Full Text] [Related]
15. Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.
Luo HC; Cheng LP; Cheng HH; Fu ZC; Liao SG; Li DS; Zheng WF; Lin GS; Zhu JF; Xu JF; Yin Q; Yu QY
Med Oncol; 2014 Jun; 31(6):991. PubMed ID: 24848281
[TBL] [Abstract][Full Text] [Related]
16. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
[No Abstract] [Full Text] [Related]
17. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
[TBL] [Abstract][Full Text] [Related]
18. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
[TBL] [Abstract][Full Text] [Related]
19. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
de la Taille A
World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
[No Abstract] [Full Text] [Related]
20. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]